MAIA Biotechnology Q3 net loss narrows to $3.9M; cash of $14.1M supports 12-month runway

MAIA Biotechnology, Inc.

2022-Q3 EPS reported -$1.40

Cash totaled $14.1M as of Sep 30, 2022, up from $10.6M at Dec 31, 2021; proceeds from July IPO added.
R&D expenses rose to $2.3M (Q3 2022) vs $1.1M (Q3 2021) due to THIO trial startup and clinical prep.
Net loss improved to $3.9M (Q3 2022) from $5.2M (Q3 2021), primarily due to prior-year loss on convertible notes.
Presented THIO-101 Phase 2 trial design at ESMO 2022; plans to report safety data in Q4 2022 and efficacy data in 2023.
Added to Longevity Stock Index; preclinical data for THIO in hepatocellular carcinoma presented at Triple Meeting Symposium.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAIA Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income Net loss was approximately $3.9 million.

Period: third quarter ended September 30, 2022
Net income: Net loss was approximately $3.9 million
Result: reported results

Exact text from the filing

MAIA Biotechnology Reports Third Quarter 2022 Financial Results

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.